	US 11,730,804 B1
	Compositions and methods for the prevention and treatment of rabies virus infection
Nathaniel Stephen Wang, San Diego, CA (US); Shigeki Joseph Miyake-Stoner, San Diego, CA (US); Parinaz Aliahmad, San Diego, CA (US); and Andrew Geall, San Diego, CA (US)
Assigned to Replicate Bioscience, Inc., San Diego, CA (US)
Filed by Replicate Bioscience, Inc., San Diego, CA (US)
Filed on Apr. 13, 2022, as Appl. No. 17/720,002.
Int. Cl. C12N 15/86 (2006.01); C07K 7/00 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/12 (2013.01) [C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/5258 (2013.01); C12N 2770/36122 (2013.01); C12N 2770/36134 (2013.01); C12N 2770/36143 (2013.01); C12N 2770/36145 (2013.01); C12N 2770/36162 (2013.01)]

26 Claims

1. A nucleic acid construct comprising a nucleic acid sequence encoding a modified alphavirus genome or self-replicating RNA (srRNA),

wherein the modified alphavirus genome or srRNA comprises no nucleic acid sequence encoding viral structural proteins required for viral particle formation,

wherein the nucleic acid sequence encoding the viral structural proteins of the modified alphavirus genome or srRNA has been replaced by a coding sequence for a polypeptide construct comprising an envelope glycoprotein G of a rabies virus (RABV-G), a variant thereof, or an antigenic determinant of either thereof, and

wherein the nucleic acid construct comprises the nucleic acid sequence of SEQ ID NO: 2 and SEQ ID NO: 3.